Sichuan Kelun Pharmaceutical Research Institute — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

The R&D engine of Kelun Group, developing novel small molecule drugs for oncology and infectious diseases.

OncologyInfectious Disease

Integrated small molecule and biologics discovery platforms, with a strong focus on antibody-drug conjugate (ADC) technology.

Leveraging China's large patient population for efficient clinical trials and potential for out-license deals on novel assets to global partners.

Clinical and commercial risk associated with entering highly competitive therapeutic areas with potentially me-too products.

Faces intense competition in oncology from global pharma giants and a crowded field of domestic Chinese biotechs also pursuing ADC technology.